SPARC/osteonectin is Involved in Metastatic Process to the Lung During Melanoma Progression

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2014 Jul 5

PMID 24993904

Citations 8

Authors

Gerardo Botti

Giosue Scognamiglio

Laura Marra

Francesca Collina

Maurizio di Bonito

Margherita Cerrone

Bruna Grilli

Annamaria Anniciello

Renato Franco

Franco Fulciniti

Paolo Antonio Ascierto

Monica Cantile

Affiliations

Soon will be listed here.

Abstract

The existence of a "metastasis gene signature" that predisposes primary breast cancer cells to metastasize to the lungs has been recently highlighted by gene expression profiling studies. The combination of genes responsible for this process includes genes encoding several metalloproteinases as well as the gene encoding SPARC (secreted protein acidic and rich in cysteine)/osteonectin. SPARC is involved in normal tissue remodeling as it regulates the deposition of extracellular matrix, but also plays a role in neoplastic transformation. Aberrant SPARC expression has been detected both in stromal cells associated with cancer and in cancer cells. The main aim of this study was to investigate whether or not SPARC might be involved in directing metastasis of other types of cancer to the lung. We constructed a tissue microarray containing lung metastases from a variety of primary tumors in different organs and used immunohistochemistry to assess SPARC expression. We found SPARC overexpressed mainly in lung metastases from melanoma. We then assessed the expression of SPARC mRNA and protein in metastatic melanoma from different anatomic sites and in their corresponding primary tumors, and found that it is overexpressed in lung metastases. Our data strongly support the hypothesis that SPARC is involved in directing melanoma metastases specifically to the lung, which underpins its potential as prognostic marker and novel target for specific therapy.

Citing Articles

SMOC2 promotes an epithelial-mesenchymal transition and a pro-metastatic phenotype in epithelial cells of renal cell carcinoma origin.

Feng D, Gao P, Henley N, Dubuissez M, Chen N, Laurin L Cell Death Dis. 2022; 13(7):639.

PMID: 35869056 PMC: 9307531. DOI: 10.1038/s41419-022-05059-2.

Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.

Akil H, Rouanet J, Viallard C, Besse S, Auzeloux P, Chezal J Transl Oncol. 2019; 12(11):1442-1452.

PMID: 31421458 PMC: 6704444. DOI: 10.1016/j.tranon.2019.07.015.

Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer.

Liao P, Li W, Liu R, Teer J, Xu B, Zhang W Onco Targets Ther. 2018; 11:6969-6980.

PMID: 30410354 PMC: 6199229. DOI: 10.2147/OTT.S173934.

Biomacromolecules as carriers in drug delivery and tissue engineering.

Zhang Y, Sun T, Jiang C Acta Pharm Sin B. 2018; 8(1):34-50.

PMID: 29872621 PMC: 5985630. DOI: 10.1016/j.apsb.2017.11.005.

Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Coury J, Davis B, Koumas C, Manzano G, Dehdashti A Neurosurg Rev. 2018; 43(1):41-48.

PMID: 29666970 DOI: 10.1007/s10143-018-0978-5.

References

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Minn A, Gupta G, Siegel P, Bos P, Shu W, Giri D . Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050):518-24. PMC: 1283098. DOI: 10.1038/nature03799. View

Uehara H, Luo L, Simonis J, Singh N, Taylor E, Ambati B . Anti-SPARC oligopeptide inhibits laser-induced CNV in mice. Vision Res. 2009; 50(7):674-9. PMC: 2840068. DOI: 10.1016/j.visres.2009.12.003. View

Ledda M, Adris S, Bravo A, Kairiyama C, Bover L, Chernajovsky Y . Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997; 3(2):171-6. DOI: 10.1038/nm0297-171. View

Chlenski A, Guerrero L, Peddinti R, Spitz J, Leonhardt P, Yang Q . Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer. 2010; 9:138. PMC: 2895596. DOI: 10.1186/1476-4598-9-138. View

Massi D, Franchi A, Borgognoni L, Reali U, Santucci M . Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999; 30(3):339-44. DOI: 10.1016/s0046-8177(99)90014-x. View

Yang E, Kang H, Koh K, Rhee H, Kim N, Kim H . Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer. 2007; 121(3):567-75. DOI: 10.1002/ijc.22706. View

Chlenski A, Liu S, Crawford S, Volpert O, DeVries G, Evangelista A . SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002; 62(24):7357-63. View

Puolakkainen P, Brekken R, Muneer S, Sage E . Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res. 2004; 2(4):215-24. View

10.

de Souza C, Xander P, Monteiro A, Silva A, da Silva D, Mai S . Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PLoS One. 2012; 7(9):e44800. PMC: 3439384. DOI: 10.1371/journal.pone.0044800. View

11.

Watanabe T, Kobunai T, Tanaka T, Ishihara S, Matsuda K, Nagawa H . Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum. 2009; 52(12):1941-8. DOI: 10.1007/DCR.0b013e3181b53684. View

12.

Bellahcene A, Castronovo V . Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995; 146(1):95-100. PMC: 1870781. View

13.

Wong G, Rustgi A . Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer. 2013; 108(4):755-61. PMC: 3590656. DOI: 10.1038/bjc.2012.592. View

14.

Cantile M, Scognamiglio G, Anniciello A, Farina M, Gentilcore G, Santonastaso C . Increased HOX C13 expression in metastatic melanoma progression. J Transl Med. 2012; 10:91. PMC: 3478206. DOI: 10.1186/1479-5876-10-91. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Brekken R, Sage E . SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001; 19(8):816-27. DOI: 10.1016/s0945-053x(00)00133-5. View

17.

Chlenski A, Cohn S . Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol. 2009; 21(1):55-65. DOI: 10.1016/j.semcdb.2009.11.018. View

18.

Ledda F, Bravo A, Adris S, Bover L, Mordoh J, Podhajcer O . The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol. 1997; 108(2):210-4. DOI: 10.1111/1523-1747.ep12334263. View

19.

Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho J, Fulford L . Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004; 64(9):3037-45. DOI: 10.1158/0008-5472.can-03-2028. View

20.

Navab R, Strumpf D, Bandarchi B, Zhu C, Pintilie M, Ramnarine V . Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011; 108(17):7160-5. PMC: 3084093. DOI: 10.1073/pnas.1014506108. View